Also found in: Medical.
IGF1RInsulin Growth Factor 1 Receptor
References in periodicals archive ?
Examples include CD20, (55) HER2/ neu, (56,57) platelet-derived growth factor a and p, (43,44) KIT, (58) epidermal growth factor receptor, (45,46) and IGF1R.
For example, IGF1 and oestrogen both induce MAPK activity in breast cancer cells through a mechanism involving IGF1R-mediated transactivation of the EGFR [42-44] whilst blockade of IGF1R signalling or inhibition of ER expression has been shown to abrogate oestrogen or IGF1 response respectively [45], further supporting cross-talk between the ER and IGF1R signalling pathways.
Our results showed cell-specific localization in the FSHR and IGF1R during the maturation of somatic and germinal compartments of bovine COC.
Polymorphisms of the IGF1R gene and their genetic effects on chicken early growth and carcass traits.
2008) evaluation of combinational therapy using an anti-cancer agent and an IGF1R inhibitor compound Phyto- This invention 2008/ Rangel and nutraceurical demonstrates that a US20080260771 Angel synergistic specific (2008) composition combination of for Prostate extracts of plants disorder(s) and nutraceuticals possess synergistic effects, with minimal side effects for treatment of prostate disorders Compositions and This invention is 2008/ Majeed (2008) methods to related to a U520080226571 provide composition enhanced containing photoprotection Labdane- against UV A and diterpenoids that UV induced provides better insult of human photo skin protection against both UV A and UV A radiations in the HaCaT human keratinocyte cell lines.
Conversely, as detailed in Figure 1, in addition to its effects on transcription, oestrogen-bound ER has also been shown to result in non-genomic effects via rapid activation of EGFR [9], IGF1R [10], HER2 [41] or the cleavage of membrane-bound growth factor receptor ligands such as epidermal growth factor or transforming growth factor [alpha] [13].
Transient modulation of glucose and insulin, which can be attributed to inhibition of IGF1R and insulin receptor signaling, was observed and resulted in mild to moderate (Grade 1/2) asymptomatic hyperglycemia, which resolved within a few hours.
Among the intracellular components in the insulin-signaling pathway, IGF2 expression was the most abundant, followed by AKT1, IGF2R, INSR, IRS1 and IGF1R, but the mRNA levels of INS1, INS2, PIK3CB, and SHC1 were very low in the adipocytes.
Encouraging data on several of the compounds, including XL184 (MET, RET, VEGFR2), XL281 (RAF), and XL228 (BCR-ABL, IGF1R, SRC), were presented at the EORTC-NCI-AACR meeting this week, and there will be additional data presented on XL228 at the American Society of Hematology (ASH) meeting in December.
Inhibitor of IGF1R and SRC Shows Early Signs of Clinical Benefit
These clinical studies will include analyses of exploratory pharmacodynamic markers associated with the inhibition of IGF1R signaling by OSI-906.
Inhibitor of BCR-ABL, SRC, and IGF1R Shows Early Signs of Clinical Benefit in Patients With Resistant CML or Ph+ ALL